Renal denervation: One potential therapeutic target for comorbid diabetes mellitus and worsening heart failure

2014 ◽  
Vol 177 (1) ◽  
pp. 37-38
Author(s):  
Tao Tu ◽  
Yichao Xiao ◽  
Shenghua Zhou ◽  
Qiming Liu
2007 ◽  
Vol 13 (6) ◽  
pp. S22-S23
Author(s):  
Yutaka Kagaya ◽  
Yasuhide Asaumi ◽  
Tomohiro Tada ◽  
Nobuyuki Shiba ◽  
Kunio Shirato ◽  
...  

2011 ◽  
Vol 15 (11) ◽  
pp. 2443-2451 ◽  
Author(s):  
Shiang Y. Lim ◽  
Derek J. Hausenloy ◽  
Sapna Arjun ◽  
Anthony N. Price ◽  
Sean M. Davidson ◽  
...  

Author(s):  
Sahrai Saeed ◽  
Hannes Holm ◽  
Peter Nilsson

Patients with type 2 diabetes (T2D) are at high risk of cardiovascular complications. Novel anti-diabetic medications such as sodium-glucose cotransporter-2 inhibitors (SGLT-2i) and Glucagon-like peptide-1 receptor agonists (GLP-1RA) have been shown to possess cardiac and renal protective effects beyond their ability to lower plasma glucose. Use of SGLT-2i and GLP-1RA in patients with T2D and heart failure reduce cardiovascular risk and heart failure related hospitalizations. SGLT-2i treatment has shown to improve the long-term prognosis of patients with heart failure. Both drugs also have the potential to normalize ventricular-arterial coupling (VAC). VAC is the crosstalk between the left ventricular function and the arterial system, and is an indicator of the global cardiovascular performance. In this overview, we will describe the concept of VAC and the features of diabetic cardiomyopathy, as well as VAC as a potential therapeutic target in diabetes by use of novel anti-diabetic drugs, primarily SGLT-2i and GLP-1RA. Continuous...


2018 ◽  
Vol 19 (10) ◽  
pp. 3205 ◽  
Author(s):  
Katarzyna Skórzyńska-Dziduszko ◽  
Żaneta Kimber-Trojnar ◽  
Jolanta Patro-Małysza ◽  
Agnieszka Stenzel-Bembenek ◽  
Jan Oleszczuk ◽  
...  

Gestational diabetes mellitus (GDM) is a complex condition that involves a variety of pathological mechanisms, including pancreatic β-cell failure, insulin resistance, and inflammation. There is an increasing body of literature suggesting that these interrelated phenomena may arise from the common mechanism of endoplasmic reticulum (ER) stress. Both obesity-associated nutrient excess and hyperglycemia disturb ER function in protein folding and transport. This results in the accumulation of polypeptides in the ER lumen and impairs insulin secretion and signaling. Exercise elicits metabolic adaptive responses, which may help to restore normal chaperone expression in insulin-resistant tissues. Pharmacological induction of chaperones, mimicking the metabolic effect of exercise, is a promising therapeutic tool for preventing GDM by maintaining the body’s natural stress response. Metformin, a commonly used diabetes medication, has recently been identified as a modulator of ER-stress-associated inflammation. The results of recent studies suggest the potential use of chemical ER chaperones and antioxidant vitamins as therapeutic interventions that can prevent glucose-induced ER stress in GDM placentas. In this review, we discuss whether chaperones may significantly contribute to the pathogenesis of GDM, as well as whether they can be a potential therapeutic target in GDM treatment.


2007 ◽  
Vol 4 (4) ◽  
pp. 207-213 ◽  
Author(s):  
Filippo Brandimarte ◽  
Francesco Fedele ◽  
Leonardo De Luca ◽  
Gregg C. Fonarow ◽  
Mihai Gheorghiade

2012 ◽  
Vol 18 (2) ◽  
pp. 123-134 ◽  
Author(s):  
Mihai Gheorghiade ◽  
Catherine N. Marti ◽  
Hani N. Sabbah ◽  
Lothar Roessig ◽  
Stephen J. Greene ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document